Finnish researchers discover regulator of human cell activity
The research teams headed by Prof. Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) and Prof. Marko Salmi (University of Turku and the National Institute for Health and Welfare) have discovered that the SHARPIN protein regulates human cell activity.
Published in a leading journal, the study concludes that SHARPIN regulates the movement and activity of inflammatory cells and of lung and prostate cancer cells. It is likely that the discovery will also have significant implications for other conditions such as Crohn’s disease, psoriasis, rheumatism and even MS.
The hypothesis that there must be a protein that inhibits cell activity was posited as far back as in the early 1990s. Researchers have now shown that SHARPIN is the hypothesised protein.
Juha Rantala and Jeroen Pouwels, members of Prof. Ivaska’s research team, discovered the role of SHARPIN using a cell chip screening method developed at VTT. Using this method, the impacts of all genes in an entire genome can be examined in a single test.
The study was published in Nature Cell Biology.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Libraries for Proteins - Dynamic combinatorial libraries generated from hydrazone-functionalized surface mimetics
Toward fixing damaged hearts through tissue engineering

Researchers design a pulsing nanomotor - Machine measures just one ten-thousandth of a millimeter: An alphabet soup serves as fuel

Proximagen Group plc. - London, United Kingdom
MorphoSys received a milestone payment from Janssen - Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis
Brown-Séquard_syndrome
Destroying_angel
Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
SEQUENOM and National Institutes of Health Expand Relationship for Gene Expression - Agreement Builds on Success of Previous SNP Genotyping Research
Anti-gliadin_antibodies

Miraculous proliferation
